Abstract
Background: Cardiovascular diseases (CVDs) are one of the main factors responsible for human morbidity and mortality. Since mitochondria play a critical role in the regulation of cardiac tissue homeostasis, this organelle is a critical target for the protective effects of several pharmaceuticals. Although specific mitochondria-targeted antioxidants and some pharmacological agents are described as potential cardioprotective agents, there are still a few effective mitochondrial therapies for the treatment of CVDs. Agents which have potential cardioprotective effects by directly targeting mitochondria in vitro and in vivo are still in pre-clinical or clinical trials, hence their widespread use in the clinic is still far. Also, some of these agents have a decreased bioavailability or show some intrinsic toxicity, which also limits their working mitochondrial concentrations.
Methods: By initially using PubMed specific queries for literature search, we review here cardiac mitochondrial effects of specific targeted and non-targeted antioxidants and pharmacological agents, including MitoE, MitoQ, MitoSNO, Mito-TEMPOL, SkQ1, SkQR1, carvedilol, trimetazidine, ranolazine, diazoxide and propofol.
Results: The present review emphasizes new mitochondrial-targeting strategies which have emerged to address difficulties arising from current approaches. We also describe the strengths and weaknesses of these cardioprotective approaches.
Conclusion: Although effective therapies to target mitochondria in the context of CVDs are not under widespread clinical use, the new strategies proposed constitute a real promise for the development of therapies which may effectively prevent CVDs in the near future.
Keywords: Ischaemia-reperfusion injury, heart mitochondria, mitochondria-targeted antioxidants, cardioprotective agents, oxidative stress, calcium overload, mitochondrial permeability transition pore, mitochondrial biogenesis, drugs.
Current Pharmaceutical Design
Title:Targeting Mitochondria in Cardiovascular Diseases
Volume: 22 Issue: 37
Author(s): Filomena S.G. Silva, Rui F. Simoes, Renata Couto and Paulo J. Oliveira
Affiliation:
Keywords: Ischaemia-reperfusion injury, heart mitochondria, mitochondria-targeted antioxidants, cardioprotective agents, oxidative stress, calcium overload, mitochondrial permeability transition pore, mitochondrial biogenesis, drugs.
Abstract: Background: Cardiovascular diseases (CVDs) are one of the main factors responsible for human morbidity and mortality. Since mitochondria play a critical role in the regulation of cardiac tissue homeostasis, this organelle is a critical target for the protective effects of several pharmaceuticals. Although specific mitochondria-targeted antioxidants and some pharmacological agents are described as potential cardioprotective agents, there are still a few effective mitochondrial therapies for the treatment of CVDs. Agents which have potential cardioprotective effects by directly targeting mitochondria in vitro and in vivo are still in pre-clinical or clinical trials, hence their widespread use in the clinic is still far. Also, some of these agents have a decreased bioavailability or show some intrinsic toxicity, which also limits their working mitochondrial concentrations.
Methods: By initially using PubMed specific queries for literature search, we review here cardiac mitochondrial effects of specific targeted and non-targeted antioxidants and pharmacological agents, including MitoE, MitoQ, MitoSNO, Mito-TEMPOL, SkQ1, SkQR1, carvedilol, trimetazidine, ranolazine, diazoxide and propofol.
Results: The present review emphasizes new mitochondrial-targeting strategies which have emerged to address difficulties arising from current approaches. We also describe the strengths and weaknesses of these cardioprotective approaches.
Conclusion: Although effective therapies to target mitochondria in the context of CVDs are not under widespread clinical use, the new strategies proposed constitute a real promise for the development of therapies which may effectively prevent CVDs in the near future.
Export Options
About this article
Cite this article as:
Silva S.G. Filomena, Simoes F. Rui, Couto Renata and Oliveira J. Paulo, Targeting Mitochondria in Cardiovascular Diseases, Current Pharmaceutical Design 2016; 22 (37) . https://dx.doi.org/10.2174/1381612822666160822150243
DOI https://dx.doi.org/10.2174/1381612822666160822150243 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry Patent Selections:
Recent Patents on Biomarkers Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Antinociceptive and Anti-Inflammatory Like Effects of <i>Berberis baluchistanica</i>
Current Molecular Pharmacology The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation
Current Pharmaceutical Design Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation
Current Drug Targets Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure
Current Pharmaceutical Design Synthesis and Characterization of a Nylon/Titanium as Hybrid Biomaterial
Recent Patents on Corrosion Science (Discontinued) Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes
Recent Patents on Cardiovascular Drug Discovery TNF-α/Cycloheximide-Induced Oxidative Stress and Apoptosis in Murine Intestinal Epithelial MODE-K Cells
Current Pharmaceutical Design The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry Microbubbles as Drug Delivery Systems in Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Meet our Editor (Pharmacology)
Current Chinese Science